Jump to content

Harrison Stafford

Legacy Members
  • Posts

    2912
  • Joined

  • Last visited

Everything posted by Harrison Stafford

  1. Im actually enjoying a stress free frame of mind so far knowing the Astros are probably entering a rebuilding era by seasons end. The biggest disappointment has been Hader. The cash spent on him could have kept Neris, Maton, and Stanek with plenty left over. Am not thrilled with the GM or the field manager who had no managing experience prior to this season. It’s one of those “I don’t give a shit” seasons….which we haven’t had in some time.
  2. Unfortunately for Marvin, his pops listened to “I Heard It Through The Carbine”.
  3. You gots to mention Trey Moore, Justice Finkley, Colin Simmons and Colton Vasek in the EDGE equation as well. This may be the deepest we’ve been at EDGE in my lifetime and I’m old. How old? Well, when you’re a teenager and someone falls, it’s the funniest shit ever. Now, it’s depressing.
  4. Skowronek was the Rams special teams captain last season.
  5. They wouldn’t have us playing like shit. And the bigger, brighter picture wound be the long term potential for the organization. We really fucking need their help.
  6. We need to bring back Luhnow and Hinch.
  7. We’re playing like shit.
  8. I could be wrong. If PSS doesn’t sell the company, in that case, we’re on the ground floor of the next big pharma company.
  9. It wouldn’t shock me if Joe Espada got axed by the All-Star break if things don’t turn around in a big way. The team is playing bad, unmotivated baseball and that’s on the manager.
  10. Short term, there’s a distinct possibility of a seismic short squeeze to propel the sp of IBRX much higher. Long term, Patrick Soon-Shiong sells IBRX to Merck, BMS, or Roche in 2024, 2025, or 2026 at a value reflecting a sp of $50+. They all have patent cliffs coming real soon with Keytruda, Opdivo, and Tecentriq, respectively. Now, you can add Anktiva to their drug to extend the benefit and extending the runways of their drugs until Anktiva’s patent cliff in 2035. Plus, the only way Patrick Soon-Shiong maximizes Anktiva is by selling to Big Pharma enabling sales in China, Japan, and the rest of world, not just the handful of markets they had on that slide in last Friday’s presentation. And Patrick Soon-Shiong is 71 years old. Would you like to try and put together a global sales force at 71?
  11. As of the April 15th report, 54.838 million shares of IBRX were sold short. That’s up about 75,000 shares from the end of March. If they can get a squeeze going, IBRX will be something to behold.
  12. Now, GERN +.42 to $4.21.
  13. IBRX is supposed to begin shipping Anktiva May 6th. Anktiva will become the standard of care treating bladder cancer. You mos def want to make your sister aware of this drug!
  14. GERN +.21 to $4.
  15. I dont think people understand the importance of IBRX’s news last week regarding treating lung cancer. With the trial results in 2nd line and 3rd line lung cancer and Anktiva being an approved drug in bladder cancer, a label expansion is not going to be nearly as difficult as a new set of trials (Phase 1, Phase 2, Phase 3). In fact, The FDA could fast track this treatment. IBRX + 2.35 to $9.70.
  16. The beginning of glam rock.
  17. My wife did her undergrad studies at South Dakota State and I’ve seen the Janke twins play a number of times over the past two seasons. This is a solid FA signing and I like their chances of sticking as special teams/WR.
  18. Unless it’s Kenyon Green.
  19. Nickel back at the very least.
  20. 40% of IBRX’s float is sold short. We’re going to a nice squeeze. The question is when. IBRX +2.12 to $7.24.
  21. So, IBRX concluded their conference call/webcast a few minutes ago and the stock is +1.12 to $6.23. IBRX….the next big thing
  22. Man, if I can’t sell you on IBRX, I’ve lost my touch.. You might look at Geron (GERN). Their PDUFA date is June 16th for their blood cancer drug, Imetelstat. AdCom voted 12-2 in favor of the drug in March, so it’s likely they get FDA approval in June. MDS is a large indication and will be too tempting for Big Pharma not to scoop up Geron. It’s a 3 bagger…possibly more. Doesn’t have the massive upside of IBRX Yeah, I knew it was lengthy, but shit needed to said. I think IBRX may be on the edge of looming large.
×
×
  • Create New...